OTCMKTS:ELOX - Eloxx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.76 +0.05 (+0.39 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$12.71
Today's Range$12.46 - $13.49
52-Week Range$6.55 - $24.60
Volume25,678 shs
Average Volume34,405 shs
Market Capitalization$448.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ELOX
CUSIPN/A
Phone858-909-0749

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees15
Market Cap$448.20 million
OptionableNot Optionable

Eloxx Pharmaceuticals (OTCMKTS:ELOX) Frequently Asked Questions

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELOX."

What price target have analysts set for ELOX?

5 Wall Street analysts have issued twelve-month price targets for Eloxx Pharmaceuticals' shares. Their forecasts range from $10.00 to $31.00. On average, they expect Eloxx Pharmaceuticals' stock price to reach $22.20 in the next twelve months. This suggests a possible upside of 74.0% from the stock's current price. View Analyst Price Targets for Eloxx Pharmaceuticals.

What is the consensus analysts' recommendation for Eloxx Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eloxx Pharmaceuticals.

What are Wall Street analysts saying about Eloxx Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eloxx Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $10/share is based on an equally-weighted composite of: (a) $8.43/share, as a 35x multiple of taxed and diluted $2.58 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $12.35/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (12/24/2018)
  • 2. According to Zacks Investment Research, "Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. " (10/15/2018)

Has Eloxx Pharmaceuticals been receiving favorable news coverage?

News articles about ELOX stock have been trending somewhat positive on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eloxx Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are some of Eloxx Pharmaceuticals' key competitors?

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert E. Ward, Chairman & CEO (Age 60)
  • Dr. Silvia Noiman, Founder & Director (Age 62)
  • Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
  • Dr. Pedro Huertas, Chief Medical Officer (Age 63)
  • Dr. Colin Scott M.B., Ch.B., Medical Director (Age 66)

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.25%), Geode Capital Management LLC (0.68%), Bank of New York Mellon Corp (0.19%), Rhumbline Advisers (0.08%), MetLife Investment Advisors LLC (0.04%) and Bank of America Corp DE (0.04%). Company insiders that own Eloxx Pharmaceuticals stock include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Institutional Ownership Trends for Eloxx Pharmaceuticals.

Which institutional investors are selling Eloxx Pharmaceuticals stock?

ELOX stock was sold by a variety of institutional investors in the last quarter, including MetLife Investment Advisors LLC. View Insider Buying and Selling for Eloxx Pharmaceuticals.

Which institutional investors are buying Eloxx Pharmaceuticals stock?

ELOX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Bank of America Corp DE, Rhumbline Advisers, Metropolitan Life Insurance Co. NY, Bank of New York Mellon Corp and Citigroup Inc.. Company insiders that have bought Eloxx Pharmaceuticals stock in the last two years include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Insider Buying and Selling for Eloxx Pharmaceuticals.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $12.76.

How big of a company is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals has a market capitalization of $448.20 million. Eloxx Pharmaceuticals employs 15 workers across the globe.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is http://www.eloxxpharma.com.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 858-909-0749 or via email at [email protected]


MarketBeat Community Rating for Eloxx Pharmaceuticals (OTCMKTS ELOX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Eloxx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ELOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel